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Letter to the Editors-in-Chief
Increased prevalence of VTE reported by Klok and colleagues, the numbers don't add up
Dear Editor,
I read with interest the study by Klok and colleagues, published
April 5, 2020, entitled “Incidence of thrombotic complications in cri-
tically ill ICU patients with COVID-19.” In this study the authors report
that 31% of patients met the composite outcome of having a thrombotic
complication which they define as having a pulmonary embolism, deep
vein thrombosis, or an ischemic stroke. The study included 184 patients
with 31 patients having a thrombotic complication. This adds up to an
incidence of 16.8%, not 31%. Additionally, the authors report that 9.2%
of the patients were on therapeutic anticoagulation upon admission.
They do not report what percentage of those that made up the com-
posite outcome were already on therapeutic anticoagulation upon en-
rollment in the study. This makes it plausible that the incidence of a
true new thrombotic event was even lower than 16.8%. Finally, it is not
clear if this study was prospective or retrospective, information that
will help clinicians to weigh the validity of the results.
All hospitalized COVID-19 patients should receive chemical
thromboprophylaxis as prior research suggests that 11% of these pa-
tients would develop venous thromboembolisms (VTE) if no prophy-
lactic anticoagulation was given [1]. This has been reaffirmed by The
International Society of Thrombosis and Haemostasis in their March 25,
2020 guidelines [2].
There is concern that patients with COVID-19 are at higher risk of
developing venous thromboembolism. A recently published study
claimed that anticoagulant therapy for COVID-19 patients was asso-
ciated with decreased mortality [3]. Careful review of this study elu-
cidated that the patients received prophylactic, not therapeutic doses of
anticoagulation and thus the conclusions drawn by the authors are in-
accurate. Another study attempted to elucidate the prevalence of VTE
and reported that 25% of 81 patients with COVID-19 had a DVT. Un-
fortunately, this study is not representative as none of the 81 patients
received VTE chemical prophylaxis, making the true prevalence of VTE
in these patients unclear [4].
The American Society of Hematology recommends against empiric
therapeutic anticoagulation for COVID-19 patients given lack of evi-
dence of benefit and potential harm [5]. High quality prospective stu-
dies are required to further elucidate the best way to manage the coa-
gulopathy that we are seeing in patients critically ill with COVID-19.
Clinicians must carefully review all published work for validity before
changing practice or guidelines. Hospitals must establish safe ways to
aggressively test for the presence of VTE in these patients to inform
therapeutic anticoagulation, focusing on minimizing exposure of
healthcare workers to the virus. Dedicated imaging machines located
close to patients with COVID-19 can help improve the ability to rapidly
diagnose and treat VTE in patients with COVID-19.
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